2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.
about
Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer ActivitiesDocking screens: right for the right reasons?Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73.ΔF508-CFTR correctors: synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles.Selectivity and potency of cyclin-dependent kinase inhibitors.Synthesis, Characterization and Molecular Docking of Novel Bioactive Thiazolyl-Thiazole Derivatives as Promising Cytotoxic Antitumor Drug.Cyclin Dependent Kinase 9 Inhibitors for Cancer TherapyRecent progress in the discovery and development of cyclin-dependent kinase inhibitors.Click-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis.Ligand discovery and virtual screening using the program LIDAEUS.Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replicationInhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cellsUnveiling new chemical scaffolds as Mnk inhibitors.Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.Discovery of nitroaryl urea derivatives with antiproliferative properties.Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities.Synthesis of novel thiazolyl-pyrimidines and their anticancer activity in vitro.CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83.Strong nonadditivity as a key structure-activity relationship feature: distinguishing structural changes from assay artifacts.Molecular docking and biological evaluation of some thioxoquinazolin-4(3H)-one derivatives as anticancer, antioxidant and anticonvulsant agents.Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors.Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform.A systematic analysis of atomic protein-ligand interactions in the PDB.Synthesis, anti-angiogenic and DNA cleavage studies of novel N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide derivatives.Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.Evaluating the enthalpic contribution to ligand binding using QM calculations: effect of methodology on geometries and interaction energies.Classical anticytokinins do not interact with cytokinin receptors but inhibit cyclin-dependent kinases.Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
P2860
Q27675842-E22DAB51-BD8E-4409-A567-BC3E24B5893DQ30380679-99176C59-0318-4BE7-97F6-2D6D12E41448Q34365839-18F31FDC-E838-4C4D-BA5D-656ECA6F70D8Q34628552-CC5085A8-2747-47D1-B386-8379B87E67B2Q34651981-D872E3D3-9F44-4527-87AD-5DD1E22C7139Q35878338-D268F2A5-E206-4C16-AF96-35D0473E84F1Q36015334-6113B675-B625-4C27-875A-CB910595FF6CQ36120794-E31D2AF4-7AFB-44B5-A0E5-F021931C53E2Q36166335-BBFFD4F4-DC6E-4E8C-8F64-815F953E7CC1Q36496975-0EE49F6E-FCBD-4EB5-A07D-A898782ECEDAQ37368099-A9BAB8C0-80FD-42D4-B694-79C3A1881842Q37636705-F738E079-6365-455F-8DBA-28C9BDEE106EQ38791406-F654179C-96F5-4010-9C0C-3E616FC83588Q38806786-D455C4F7-8B94-410C-B280-F680D6EDF50CQ38859827-20DE3410-583A-4B67-83F9-59267952D88CQ39010703-C725AA75-A513-4C1B-9834-E6009D5E4B12Q39458388-C123C74B-8AC2-4C82-8BFE-B4F118979F61Q39460991-144E57EC-A327-4774-9665-646ECBAAFB43Q39560150-E78950D6-365D-4835-AC7B-6D7EF856842DQ39589955-37A3AFB7-C466-430E-B7F4-BDC501FD52A1Q41245616-D32B7348-1BFE-4FDE-AC1F-E15D3E025F56Q42813308-730AC491-A676-42CF-A8A9-65AAED121FFBQ44207658-9D17C11C-99B6-498F-A1B3-42A1A6E2AEBEQ45947436-5720C88D-36F3-44F9-AE19-D685421579A4Q47098164-0AF8C0B1-2530-46F5-AADB-9F4D8FA58929Q47154777-A9478186-D430-4013-86D8-B48E2BD1C81FQ47611731-4CED44E2-411B-4C90-8D05-DFC880A92872Q50711550-AAF1B376-192C-403F-BE80-E4C484872EFFQ51601126-A890234E-0D0F-4222-92C9-3DC367D7BB6BQ51992710-9C33954E-6E6F-43FD-8F3E-DF41B9D31A94Q54234353-61FD9F53-FEC5-4E66-A275-4883ACCE3138
P2860
2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
2-Anilino-4-(thiazol-5-yl)pyri ...... aphy, and biological activity.
@en
type
label
2-Anilino-4-(thiazol-5-yl)pyri ...... aphy, and biological activity.
@en
prefLabel
2-Anilino-4-(thiazol-5-yl)pyri ...... aphy, and biological activity.
@en
P2093
P50
P356
P1476
2-Anilino-4-(thiazol-5-yl)pyri ...... aphy, and biological activity.
@en
P2093
Andrew Osnowski
Campbell McInnes
Carol Midgley
Christopher Meades
Daniella Zheleva
Gary Griffiths
Gavin Wood
Ian Fleming
Mark Thomas
Mokdad Mezna
P304
P356
10.1021/JM0309957
P407
P577
2004-03-01T00:00:00Z